People news from the 01/02/07 news brief

MANUFACTURERS Pfizer’s board of directors has elected CEO Jeff Kindler as its chairman, succeeding Hank McKinnell. McKinnell will step down from the Board when he leaves the company in February. The Board of Directors of Merck has elected CEO Richard Clark as chairman of the board effective April 24, 2007, the date of the Merck annual meeting of stockholders. Clark has been CEO of Merck since May 2005. The board also appointed Samuel Thier as lead director. GlaxoSmithKline named Adrian Rawcliffe SVP, worldwide business development, research & development, effective immediately. Rawcliffe most recently served as managing partner and president, SR One Ltd., GSK's venture-capital business. Valeritas, a subsidiary of BioValve Technologies, has hired Tara Charvat as VP of marketing and marketing operations. Charvat joins the company with a diverse background in pharmaceutical marketing, having held key positions at Saatchi & Saatchi Healthcare Advertising, Publicis Medical Education Group, and Abbott Laboratories. In her newly created position, Charvat will play a major role in creating innovative, integrated promotional campaigns for Valeritas' metabolic portfolio of products as well as coordinating the company's product marketing programs. Her immediate priority will be to develop and execute an integrated marketing plan for the company's lead product, h-Patch insulin delivery system, which is scheduled for commercial launch in the second half of 2007, the company said in a statement. AGENCIES Imc²'s Philadelphia office has hired five additional employees -- Lisa Eckel, Jeanille Tumey and Danielle Brose join as project managers; Karen Angelucci joins as an account manager, while Yvonne Connolly serves as an executive assistant. SUPPLIERS IMS Health elected Bret Wise, president and COO of Dentsply International, to its board of directors, effective immediately.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.